---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-23-000036"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2023-06-06T23:59:59+00:00"
generated_at: "2026-06-14T06:40:15.052299+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Keros shareholders elect Gordon, Kariv as directors; ratify Deloitte as auditor

## Summary
- Carl L. Gordon elected with 11.5M votes for, 13.4M withheld, 1.9M broker non-votes.
- Tomer Kariv elected with 19.2M votes for, 5.7M withheld, 1.9M broker non-votes.
- Ratification of Deloitte & Touche as independent auditor approved: 26,790,800 for, 2,224 against, 1 abstain.
- No broker non-votes on auditor ratification proposal.

## SEC filing metadata
- accession: 0001664710-23-000036
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2023-06-06T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000036/0001664710-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000036/kros-20230606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-23-000036
- JSON: https://secwatch.observer/filing/0001664710-23-000036.json
- Plain text: https://secwatch.observer/filing/0001664710-23-000036.txt

## Key facts
- Shareholder Votes
  Keros Therapeutics, Inc. shareholders approved Ratification of the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2023 The Company’s stockholders approved Proposal 2. The votes cast were as follows: Votes For Votes Against Votes Abstain 26,790,800 2,224 1 There were no broker non-votes with respect to Proposal 2.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000036/0001664710-23-000036-index.htm
- Shareholder Votes
  Keros Therapeutics, Inc. shareholders approved Election of two nominees for director to hold office until the Company’s 2026 Annual Meeting of Stockholders at the 2023-06-06 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal 1 – Election of Directors The Company’s stockholders elected the two persons listed below as directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Carl L. Gordon 11,486,998 13,409,802 1,896,225 Tomer Kariv 19,234,712 5,662,088 1,896,225
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000036/0001664710-23-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.